Succeeding in Heart Failure, Incrementally

Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.

Heart failure (HF), like cancer, is a major killer--in the US alone, 5.2 million people die from it; another 550,000 are diagnosed with it each year. Younger patients can expect to die within five years of diagnosis; elderly within one.

But like cancer, HF is more a convenient description of a set of diseases and conditions than it is itself a disease. The American College of Cardiology and the American...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business